查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618624

黑色素瘤治疗药物市场：按类型、产品和分销管道划分 - 全球预测 2025-2030

Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年黑色素瘤治疗市场价值为54亿美元，预计2024年将达到58.1亿美元，复合年增长率为8.32%，预计到2030年将达到94.5亿美元。

黑色素瘤治疗市场包括一系列用于检测、预防和治疗黑色素瘤的治疗方法，黑色素瘤是一种主要由黑色素产生细胞产生的严重皮肤癌。由于长期紫外线照射和遗传倾向等因素，全球黑色素瘤发生率不断增加，因此需要有效的治疗方法，因此需要黑色素瘤治疗。其应用涵盖个人化医疗、免疫治疗、标靶治疗和化疗，为医院、诊所、癌症研究机构和专科医疗中心等主要最终用户提供服务。关键的成长要素包括生物技术的进步、研发投资的增加、政府促进癌症早期检测的努力以及黑色素瘤盛行率的上升推动了对创新药物的需求。最新的机会在于开发个人化免疫疗法和联合治疗解决抗药性并提高现有疗法的有效性。为了抓住这些机会，将透过投资尖端研究、与生物技术公司合作以及在药物发现中利用人工智慧来推动成长。然而，高昂的治疗成本、严格的监管要求和潜在的副作用等挑战限制了其采用。此外，学名药的竞争和早期诊断的挑战（需要明确的治疗方法）也限制了市场的成长。开拓这个市场可能会围绕着开发副作用较少的药物、使用 CRISPR 基因编辑技术以及创建针对不同患者情况的综合组合方案。研究可以进一步探索奈米技术与生物製药的融合。市场动态本质上是动态的，受到科学进步和对有效解决方案的迫切需求的推动，而成长需要策略性地应对独特的挑战和监管环境，这提供了许多途径。

主要市场统计
基准年[2023] 54亿美元
预计年份 [2024] 58.1亿美元
预测年份 [2030] 94.5亿美元
复合年增长率（%） 8.32%

市场动态：揭示快速发展的黑色素瘤药物市场的关键市场洞察

供需的动态交互作用正在改变黑色素瘤药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球黑色素瘤和其他皮肤癌盛行率不断上升
    • 政府增加医疗保健支出
    • 癌症领域生物相似药开发活性化
  • 市场限制因素
    • 与药物开发和治疗相关的高成本
  • 市场机会
    • 对减少副作用和高效率的标靶治疗的需求不断增加
    • 持续研发努力推出有效药物
  • 市场挑战
    • 严格的监管政策和漫长的核准流程

波特的五力：驾驭黑色素瘤药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对黑色素瘤药物市场的影响

外部宏观环境因素在塑造黑色素瘤治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解黑色素瘤治疗药物市场的竞争状况

对黑色素瘤治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵黑色素瘤治疗市场供应商的绩效评估

FPNV 定位矩阵是评估黑色素瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘黑色素瘤治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对黑色素瘤治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球黑色素瘤和其他皮肤癌的发生率不断上升
      • 政府增加医疗保健支出
      • 推动肿瘤领域生物相似药的发展
    • 抑制因素
      • 药物开发和治疗成本高昂
    • 机会
      • 对副作用更少、效率更高的标靶治疗的需求不断增加
      • 继续进行旨在推出有效药物的研究和开发活动
    • 任务
      • 严格的监管政策和漫长的核准流程
  • 市场区隔分析
    • 类型：肢端恶性黑色素瘤和恶性黑色素瘤对非侵入性治疗方法的需求不断增加
    • 产品：对治疗恶性黑色素瘤疾病进展和基因突变的下一代药物的需求增加
    • 分销管道：由于便利和远端医疗支持，对线上管道的需求不断增长
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章黑色素瘤治疗药物市场：依类型

  • 肢端雀斑样黑色素瘤
  • 恶性雀斑
  • 结节性黑色素瘤
  • 表浅黑色素瘤

第七章黑色素瘤治疗药物市场：副产品

  • 辅助性治疗
  • 化疗
  • 化疗药物
    • Dacarbazine(DTIC-Dome)
    • Temozolomide（Temodar）
  • 免疫治疗药物
    • 查核点抑制剂
    • CTLA-4抑制剂
  • 溶瘤病毒疗法
  • 标靶治疗
    • BRAF抑制剂
    • MEK抑制剂

第八章黑色素瘤治疗药物市场：按分销管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章北美和南美黑色素瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区黑色素瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲黑色素瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Moderna 和 Merck 报告称，与 KEYTRUDA 相比，mRNA-4157 (V940) 和 KEYTRUDA (Pembrolizumab) 的组合在高风险 III/IV 期恶性黑色素瘤患者完全切除后 3 年显示无復发生存率持续改善。了无远处转移的生存。
    • Sun Pharma 和 Philogen 的黑色素瘤治疗在 3 期试验中显示出有希望的结果
    • 美国食品药物管理局核准Opdivo （nivolumab）作为合格的IIB 期或 IIC 期恶性完全切除患者的辅助治疗
  • 战略分析和建议

公司名单

  • AB Science
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CK Life Sciences Int'l.,（Holdings）Inc.
  • Clinigen Group PLC
  • Eli Lilly and Company
  • Enzon Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Immunocore Limited
  • Merck KGaA
  • Moderna, Inc
  • Novartis AG
  • Pfizer, Inc.
  • Philogen SpA
  • Regeneron Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Wellona Pharma
Product Code: MRR-0363DFE03682

The Melanoma Drug Market was valued at USD 5.40 billion in 2023, expected to reach USD 5.81 billion in 2024, and is projected to grow at a CAGR of 8.32%, to USD 9.45 billion by 2030.

The Melanoma Drug market encompasses a range of therapeutic treatments used primarily for the detection, prevention, and therapy of melanoma, a severe form of skin cancer arising from melanin-producing cells. The necessity of melanoma drugs stems from increasing global melanoma incidences, heightened by factors such as prolonged UV exposure, and genetic predisposition, thereby necessitating effective treatments. Applications extend to personalized medicine, immunotherapy, targeted therapy, and chemotherapy, serving primary end-users such as hospitals, clinics, cancer research institutes, and specialty care centers. Key growth influencers include advancements in biotechnology, increased R&D investments, government initiatives promoting early cancer detection, and a rising prevalence of melanoma enhancing the demand for innovative drugs. Latest opportunities lie in the development of personalized immunotherapies and combination therapies that address resistance and improve the efficacy of existing treatments. To seize these opportunities, investing in cutting-edge research, collaborations with biotech firms, and leveraging AI in drug discovery can drive growth. However, challenges include the high cost of treatment, stringent regulatory requirements, and potential side effects limiting adoption. Market growth is also constrained by competition from generic drugs and the challenge of early-stage diagnosis requiring distinct treatment approaches. Innovations in this market could pivot around developing drugs with lower side effects, utilizing CRISPR gene-editing technology, and creating comprehensive multi-drug regimens that cater to diverse patient profiles. Research can further explore the integration of nanotechnology and biopharmaceuticals. The melanoma drug market is dynamic by nature, driven by both scientific progress and an urgent need for effective solutions, presenting numerous avenues for growth while requiring strategic navigation of inherent challenges and regulatory landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 5.40 billion
Estimated Year [2024] USD 5.81 billion
Forecast Year [2030] USD 9.45 billion
CAGR (%) 8.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Melanoma Drug Market

The Melanoma Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of melanoma and other skin cancers globally
    • Increase in government expenditures on healthcare
    • Elevated development of biosimilar in oncology arena
  • Market Restraints
    • High costs associated with drug development and treatment
  • Market Opportunities
    • Emerging need for targeted therapy owing to reduced side effects and higher efficiency
    • Ongoing research and development activities to introduce effective drugs
  • Market Challenges
    • Stringent regulatory policies and lengthy approval process

Porter's Five Forces: A Strategic Tool for Navigating the Melanoma Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Melanoma Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Melanoma Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Melanoma Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Melanoma Drug Market

A detailed market share analysis in the Melanoma Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Melanoma Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Melanoma Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Melanoma Drug Market

A strategic analysis of the Melanoma Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int'l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma.
  • Based on Product, market is studied across Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs, Immunotherapy Drugs, Oncolytic Virus Therapy, and Targeted Therapy Drugs. The Chemotherapy Drugs is further studied across Dacarbazine (DTIC-Dome) and Temozolomide (Temodar). The Immunotherapy Drugs is further studied across Checkpoint Inhibitors and CTLA-4 Inhibitors. The Targeted Therapy Drugs is further studied across BRAF Inhibitors and MEK Inhibitors.
  • Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
      • 5.1.1.2. Increase in government expenditures on healthcare
      • 5.1.1.3. Elevated development of biosimilar in oncology arena
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
      • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies and lengthy approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
    • 5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
    • 5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Melanoma Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Acral Lentiginous Melanoma
  • 6.3. Lentigo Maligna Melanoma
  • 6.4. Nodular Melanoma
  • 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Product

  • 7.1. Introduction
  • 7.2. Adjuvant Therapy
  • 7.3. Biochemotherapy
  • 7.4. Chemotherapy Drugs
    • 7.4.1. Dacarbazine (DTIC-Dome)
    • 7.4.2. Temozolomide (Temodar)
  • 7.5. Immunotherapy Drugs
    • 7.5.1. Checkpoint Inhibitors
    • 7.5.2. CTLA-4 Inhibitors
  • 7.6. Oncolytic Virus Therapy
  • 7.7. Targeted Therapy Drugs
    • 7.7.1. BRAF Inhibitors
    • 7.7.2. MEK Inhibitors

8. Melanoma Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Melanoma Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Melanoma Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Melanoma Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
    • 12.3.2. Sun Pharma and Philogen's Melanoma Drug Shows Promising Outcome in Phase 3 Trial
    • 12.3.3. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AB Science
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bristol-Myers Squibb Company
  • 6. CK Life Sciences Int'l., (Holdings) Inc.
  • 7. Clinigen Group PLC
  • 8. Eli Lilly and Company
  • 9. Enzon Pharmaceuticals, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Genentech, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Hikma Pharmaceuticals PLC
  • 14. Immunocore Limited
  • 15. Merck KGaA
  • 16. Moderna, Inc
  • 17. Novartis AG
  • 18. Pfizer, Inc.
  • 19. Philogen S.p.A.
  • 20. Regeneron Pharmaceuticals Inc.
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Taj Pharmaceuticals Limited
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MELANOMA DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 325. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 326. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023